Show simple item record

dc.contributor.authorDezsi, G
dc.contributor.authorOzturk, E
dc.contributor.authorStanic, D
dc.contributor.authorPowell, KL
dc.contributor.authorBlumenfeld, H
dc.contributor.authorO'Brien, TJ
dc.contributor.authorJones, NC
dc.date.available2014-05-22T08:12:20Z
dc.date.available2013-01-02
dc.date.available2013-01-02
dc.date.available2013-01-02
dc.date.available2013-01-02
dc.date.available2013-01-02
dc.date.available2013-01-02
dc.date.available2013-01-02
dc.date.available2013-01-02
dc.date.available2013-01-02
dc.date.issued2013-04-01
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000316965500012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4d813f4571fa7d6246bdc0dfeca3a1c
dc.identifier.citationDezsi, G., Ozturk, E., Stanic, D., Powell, K. L., Blumenfeld, H., O'Brien, T. J. & Jones, N. C. (2013). Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy. EPILEPSIA, 54 (4), pp.635-643. https://doi.org/10.1111/epi.12118.
dc.identifier.issn0013-9580
dc.identifier.urihttp://hdl.handle.net/11343/33162
dc.descriptionC1 - Journal Articles Refereed
dc.description.abstractPURPOSE: Ethosuximide (ESX) is a drug of choice for the symptomatic treatment of absence seizures. Chronic treatment with ESX has been reported to have disease-modifying antiepileptogenic activity in the WAG/Rij rat model of genetic generalized epilepsy (GGE) with absence seizures. Here we examined whether chronic treatment with ESX (1) possesses antiepileptogenic effects in the genetic absence epilepsy rats from Strasbourg (GAERS) model of GGE, (2) is associated with a mitigation of behavioral comorbidities, and (3) influences gene expression in the somatosensory cortex region where seizures are thought to originate. METHODS: GAERS and nonepileptic control (NEC) rats were chronically treated with ESX (in drinking water) or control (tap water) from 3 to 22 weeks of age. Subsequently, all animals received tap water only for another 12 weeks to assess enduring effects of treatment. Seizure frequency and anxiety-like behaviors were serially assessed throughout the experimental paradigm. Treatment effects on the expression of key components of the epigenetic molecular machinery, the DNA methyltransferase enzymes, were assessed using quantitative polymerase chain reaction (qPCR). KEY FINDINGS: ESX treatment significantly reduced seizures in GAERS during the treatment phase, and this effect was maintained during the 12-week posttreatment phase (p < 0.05). Furthermore, the anxiety-like behaviors present in GAERS were reduced by ESX treatment (p < 0.05). Molecular analysis revealed that ESX treatment was associated with increased expression of DNA methyltransferase enzyme messenger RNA (mRNA) in cortex. SIGNIFICANCE: Chronic ESX treatment has disease-modifying effects in the GAERS model of GGE, with antiepileptogenic effects against absence seizures and mitigation of behavioral comorbidities. The cellular mechanism for these effects may involve epigenetic modifications.
dc.languageEnglish
dc.publisherWILEY
dc.subjectCentral Nervous System; Nervous System and Disorders
dc.titleEthosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy
dc.typeJournal Article
dc.identifier.doi10.1111/epi.12118
melbourne.peerreviewPeer Reviewed
melbourne.affiliationThe University of Melbourne
melbourne.affiliation.departmentMedicine - Royal Melbourne Hospital
melbourne.source.titleEpilepsia
melbourne.source.volume54
melbourne.source.issue4
melbourne.source.pages635-643
melbourne.identifier.nhmrc566544
melbourne.identifier.nhmrc628466
melbourne.publicationid192535
melbourne.elementsid506284
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618492
melbourne.contributor.authorDezsi, Gabriella
melbourne.contributor.authorPowell, Kim
melbourne.contributor.authorStanic, Davor
melbourne.contributor.authorO'Brien, Terence
melbourne.contributor.authorJones, Nigel
melbourne.contributor.authorOzturk, Ezgi
dc.identifier.eissn1528-1167
melbourne.identifier.fundernameidNHMRC, 566544
melbourne.identifier.fundernameidNHMRC, 628466
melbourne.fieldofresearch320903 Central nervous system
melbourne.seocode200199 Clinical health not elsewhere classified
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record